Sunshine Biopharma Closes $6 Million Public Offering to Fund Operations and Drug Development

Sunshine Biopharma Inc. (NASDAQ: SBFM) has closed its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses. The company sold 12 million common units, each consisting of either one share of common stock or a pre-funded warrant to purchase one share of common stock, and two Series C warrants to purchase one share of common stock. If all Series C warrants are fully exercised for cash, the company could receive additional gross proceeds of approximately $12 million. Aegis Capital Corp. acted as the exclusive placement agent for the offering.

The net proceeds from the offering will be used for general corporate purposes and working capital. This capital infusion comes at a critical time as Sunshine Biopharma continues to expand its presence in the Canadian generic prescription drug market, where it currently markets 60 products. The company has announced plans to launch 12 additional generic drugs during the remainder of 2026, aiming to strengthen its revenue base and market share.

Beyond its generic drug business, Sunshine Biopharma is advancing two proprietary drug development programs. The first is K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer. The second is a PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections. These programs represent potential high-value opportunities, though they remain in early development stages and require significant additional funding and regulatory approvals.

The completion of this offering provides the company with immediate liquidity to support ongoing operations and development activities. However, the company may need to raise further capital to fully fund its research and development pipeline and achieve its strategic goals. Investors should monitor the company's progress in launching new generics and advancing its proprietary candidates, as these will be key drivers of long-term value.

For more details on the offering, the full press release is available at https://ibn.fm/XuHPC. Additional information about Sunshine Biopharma and its programs can be found on its website at https://sunshinebiopharma.com/.